Intellia Therapeutics (NTLA) Q4 2024 earnings summary

Executive summary

• Achieved strong operational execution in early 2025, with robust enrollment in three phase III programs targeting Hereditary Angioedema (HAE) and transthyretin amyloidosis (TTR); first patient dosed in global Phase 3 HAELO study for NTLA-2002, aiming for U.S. launch in 2027.

• Prioritized late-stage, high-value programs (NTLA-2002 for HAE and nex-z for TTR), discontinuing NTLA-3001 and other programs in favor of a second-generation approach; strategic review led to a 27% workforce reduction, incurring $8M in severance costs in Q1 2025.

• Positioned for three potential product launches between 2027 and 2030, with commercial readiness efforts underway.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $861.7 million as of December 31, 2024, down from $1 billion a year prior; expected to fund operations into the first half of 2027.

• Collaboration revenue was $12.9 million in Q4 2024, up from negative $1.9 million in Q4 2023, mainly due to Regeneron agreements.

• R&D expenses rose to $116.9 million in Q4 2024 (from $109 million), driven by lead program advancement; G&A expenses increased to $32.4 million (from $29 million), mainly due to stock-based compensation.

• Net loss was $128.9 million for Q4 2024, compared to $132.2 million in Q4 2023.

• Cash runway projected into the first half of 2027.

Outlook and guidance

• Year-over-year GAAP operating expenses expected to decline by 5%-10% in 2025 due to restructuring and pipeline focus.

• Operating expenses expected to peak in 2024, with steady-state spending in 2026 and natural decline as phase III programs complete enrollment.

• HAELO Phase 3 study enrollment expected to complete in H2 2025; BLA submission planned for H2 2026.

• Anticipate increased sales and marketing investments in 2027 for NTLA-2002 launch, but overall expenses to remain below 2024 levels.

• Longer-term data from ongoing Phase 1/2 and Phase 1 studies for NTLA-2002 and nex-z expected in 2025.